In the study by Nave et al., one participant in the DCS group reported mild nausea during the hour following administration. Kleine et al. were the only ones who did not find differences between the participants in the DCS and placebo groups regarding adverse effects. At high doses administered chronically, DCS may cause side effects such as headache, drowsiness, confusion, tremors, memory difficulties, paresthesias, and seizure. In this sense, unlike many psychotropic medications, the side-effects of DCS at low doses are minimum, and therefore this drug seems to be a safe alternative for enhancing CBT outcome. Relating to the methodological quality of the included studies in this meta-analysis, most of the articles presented a low risk of bias. Figure 1 shows each article separately and figure 2 shows the Diniconazole results of summarized articles. Most part of the studies presented a low risk of bias, with one study showing a high risk of bias for incomplete outcome data and one other for description of relevant comorbidities. A significant number of the studies showed an unclear risk of bias. With Yohimbine-Hydrochloride reference to the quality of the included studies, all of them were randomized, double-blind, placebo-controlled trials, although we found a limited number of studies and with relatively small samples sizes. The study by Guastella et al. represents an exception, with a sample twice as large as in previous studies. Furthermore, we did not find any studies with generalized anxiety disorder. Regarding PTSD, we identified only two studies, both published recently. In addition to these, we located another study using DCS for treatment of chronic PTSD, but in this case the aim was to investigate the isolated benefit from prolonged use of DCS, without having the main goal of enhancing exposure therapy. In that study, treatment with DCS did not result in significant improvements as compared to the placebo group. That was the first study to investigate the efficacy of the NMDA receptor modulator in PTSD treatment. Although all studies were double-blind, no count of pills was reported in any study. In Kushner et al., ingestion of the medication at the due time was checked by telephone.